THE JAK-STAT PATHWAY: 20 YEARS FROM DISCOVERY TO DRUGS
Building 45 - Natcher
NIH campus, Bethesda
September 22-24, 2011
Day 1: Thursday, September 22
Day 2: Friday, September 23
Day 3: Saturday, September 24
Day 1: Thursday, September 22
7:30 a.m. |
Continental Breakfast / Check-in |
|
8:15 a.m. - 8:25 a.m. |
Welcome |
John O'Shea (NIH/NIAMS) |
8:25 a.m. - 9:15 a.m. |
Plenary: Where JAK-STAT Came from and One Place I Hope It Goes |
James Darnell (Rockefeller University) |
Session I |
Jaks, Signaling & Inhibitors (Chair, John O'Shea, NIH/NIAMS) |
9:15 a.m. - 9:45 a.m. |
Probing Cytokine Receptor Signaling through Imaging and Protein Engineering |
K. Christopher Garcia (Stanford University) |
9:45 a.m. - 10:15 a.m. |
Jak Inhibitors: That's a Fact, Jak! |
John O'Shea (NIH/NIAMS) |
10:15 a.m. - 10:45 a.m. |
Tofacitinib: An Investigational, Selective JAK Inhibitor for Treatment of Autoimmune Diseases |
Samuel Zwillich (Pfizer) |
10:45 a.m. - 11:15 a.m. |
BREAK |
|
11:15 a.m. - 11:45 a.m. |
JAK/STAT Signaling and MPN Phenotype |
Tony Green (Cambridge Institute for Medical Research) |
11:45 a.m. - 12:15 p.m. |
Janus Kinase Inhibition: Myelofibrosis and Beyond |
Jordan Fridman (Incyte) |
12:15 p.m. - 1:15 p.m. |
LUNCH |
|
Session II |
Jaks, Signaling & Inhibitors II (Chair, James Darnell, Rockefeller University) |
1:15 p.m. - 1:45 p.m. |
Therapeutic Opportunities Based on Oncogenic Jak Kinase Signaling in Lymphoma |
Louis Staudt (NIH/NCI) |
1:45 p.m. - 2:15 p.m. |
Targeting JAK-STAT Signaling for Cancer Therapy |
Richard Jove (City of Hope) |
2:15 p.m. - 2:45 p.m. |
Characterization of the Pseudokinase Domain of JAK2 |
Olli Silvennoinen (University of Tampere, Finland) |
2:45 p.m. - 3:00 p.m. |
Preclinical Pharmacology and Early Clinical Evaluation of GLPG0634, a Selective Jak1 Inhibitor for the Treatment of Rheumatoid Arthritis |
Gerben van't Klooster (Galapagos NV) |
3:00 p.m. - 3:15 p.m. |
Targeting STAT5 in CML: Mechanism-of-action of JAK2 Tyrosine Kinase Inhibitors Unmask a Direct BCR/ABL-STAT5 Axis |
Veronika Sexl (Veterinary University of of Vienna) |
3:15 p.m. - 3:45 p.m. |
BREAK |
|
Session III |
Biology of STATS (Chair, George Stark, Lerner Institute, Case Western) |
3:45 p.m. - 4:15 p.m. |
To Modify or Not to Modify, That Is the STAT Question |
George Stark (Lerner Institute) |
4:15 p.m. - 4:45 p.m. |
Jak-STAT Pathway and Obesity |
Andrew Larner (Virginia Commonwealth University) |
4:45 p.m. - 5:15 p.m. |
Nongenomic Functions of STAT3 |
David Levy (NYU) |
5:15 p.m. - 5:45 p.m. |
Dynamics of STAT3 Nuclear Trafficking |
Nancy Reich (Stony Brook University) |
5:45 p.m. - 6:00 p.m. |
Protein Kinase CK2 Functions as a Positive Regulator of the JAK/STAT and NF-kappaB Pathways |
Tika Benveniste (University of Alabama) |
6:00 p.m. - 6:15 p.m. |
Stat2 Directs the Stat1-independent Suppression of Legionella pneumophilaGrowth by IFN-Is |
Christian Schindler (Columbia University) |
7:30 a.m. |
Continental Breakfast |
|
Session IV |
STATs, Cancer & STAT Inhibitors (Chair, David Levy, NYU) |
8:15 a.m. - 8:45 a.m. |
The Transcription Factors Stat3 and Stat5 Are Potent Oncogenes and Promising Drug Targets |
Bernd Groner (Frankfurt) |
8:45 a.m. - 9:15 a.m. |
Selective Inhibition of Stat3 Phosphorylation with Phosphopeptidomimetic Prodrugs Targeting the SH2 Domain Inhibits the Growth of Breast Tumor Xenografts in Mice |
John McMurray (MD Anderson Cancer Center) |
9:15 a.m. - 9:45 a.m. |
Chemical Biology Approaches to Developing STAT Modulators |
David Frank (Harvard University) |
9:45 a.m. - 10:15 a.m. |
A Division of Labor between STAT5A and STAT5B in CML Pathophysiology |
Isabelle Dusanter-Fourt (INSERM/ University Paris Descartes) |
10:15 a.m. - 10:45 a.m. |
Nonconventional Approaches to Inhibition of Jak/STAT Signaling |
Nadya Tarasova (NCI) |
10:45 a.m. - 11:15 a.m. |
BREAK |
|
Session V |
STATs in Immunoregulation (Chair, Warren Leonard, NIH/NHLBI) |
11:15 a.m. - 11:45 a.m. |
STAT4 Play |
Mark Kaplan (Indiana University) |
11:45 a.m. - 12:15 p.m. |
New STATs on Memory CD4 T Cell Development |
Susan Kaech (Yale School of Medicine) |
12:15 p.m. - 12:45 p.m. |
STAT Mediated Regulation of Th Cell Differentiation |
Riitta Lahesmaa (Turku Centre for Biotechnology, University of Turku, Finland) |
12:45 p.m. - 1:15 p.m. |
STAT5 as a Modulator of Th Differentiation |
Warren Leonard (NIH/NHLBI) |
1:15 p.m. - 2:15 p.m. |
LUNCH |
|
Session VI |
Biology of STATs II (Chair, Lothar Hennighausen, NIH/NIDDK) |
2:15 p.m. -2:45 p.m. |
STAT5: From Basel to Bethesda and Beyond |
Lothar Hennighausen (NIH/NIDDK) |
2:45 p.m. - 3:15 p.m. |
Role of Stats in Lineage Determination and Cell Death Regulation in Mammary Gland |
Christine Watson (Cambridge University) |
3:15 p.m. - 3:45 p.m. |
Landscape of STAT-dependent Histone Epigenetic Modification in T Helper Cell Specification |
Yukka Kanno (NIH/NIAMS) |
3:45 p.m. - 4:15 p.m. |
Epigenetic Regulation of Interferon-gamma Signaling |
Rod Bremner (Toronto Western Hospital) |
4:15 p.m. - 4:45 p.m. |
What We Learned from Drosophila JAK & STAT |
Willis Li (UCSD) |
4:45 p.m. - 5:15 p.m. |
Activated Stat is a Supercompetitor That Acts Independently of Myc, YAP, Wnt and Ribosome Biogenesis |
Erika Bach (NYU) |
5:15 p.m. - 5:45 p.m. |
Localized JAK/STAT Signaling Maintains Tissue Shape during Morphogenesis |
Martin Zeidler (University of Sheffield) |
5:45 p.m. - 6:00 p.m. |
Chromatin associated Phosphorylation of Stat Transactivation Domains Is Catalyzed by Cdk8 of the Mediator Complex |
Pavel Kovarik (University of Vienna) |
6:00 p.m. - 6:15 p.m. |
An Essential Role of Stat3 in PI3K-induced Oncogenic Transformation |
Jonathan Hart (The Scripps Research Institute) |
6:15 p.m. |
POSTER SESSION / RECEPTION |
|
7:30 a.m. |
Continental Breakfast |
|
Session VII |
STATs & Cancer (Chair, Richard Jove, City of Hope) |
8:15 a.m. - 8:45 a.m. |
STAT3 in Cancer Inflammation and Immunity |
Hua Yu (City of Hope Medical Center) |
8:45 a.m. - 9:15 a.m. |
STAT3, Auto-immunity and Cancer: When Does Enough Become Too Much? |
Valeria Poli (University of Turin) |
9:15 a.m. - 9:45 a.m. |
The Tumorigenic Role of Stat3 in T-cell Anaplastic Large Cell Lymphoma |
Giorgio Inghirami (University of Turin) |
9:45 a.m. - 10:15 a.m. |
Single Cell Signaling & STAT Physiology in Cancer and Inflammation by Isotopic Mass Cytometry |
Garry Nolan (Stanford University) |
10:15 a.m. - 10:45 a.m. |
BREAK |
|
10:45 a.m. - 11:15 a.m. |
STAT3 Targeting in Head & Neck Cancer |
Jennifer Grandis (University of Pittsburgh) |
11:15 a.m. - 11:45 a.m. |
Stat5: Oncogene and Tumor Suppressor |
Richard Moriggl (Boltzmann Institute) |
11:45 a.m. - 12:15 p.m. |
STAT3 as Inducer of Immune Evasion and Epigenetic Silencing of Tumor Suppressor Genes |
Mariusz Wasik (University of Pennsylvania) |
12:15 p.m. - 12:45 p.m. |
The Good and Evil Faces of the Janus Kinases in Heath and Disease |
Thomas Waldmann (NIH/NCI) |
12:45 p.m. - 1:00 p.m. |
Targeting the IL-6/Jak Pathway in Breast Cancer |
Jacqueline Bromberg (MSKCC) |
1:00 p.m. - 2:00 p.m. |
LUNCH |
|
Session VIII |
STATs & Infectious Disease (Chair, Manfred Boehm, NIH/NHLBI) |
2:00 p.m. - 2:30 p.m. |
Inborn Errors of Human STAT1 Immunity |
Jean-Laurent Casanova (Rockefeller University) |
2:30 p.m. - 3:00 p.m. |
Interferon and JAK-STAT Regulation by Cells and Viruses |
Curt Horvath (Northwestern University) |
3:00 p.m. - 3:30 p.m. |
Hyper IgE Syndrome: From Wound Healing to Cell Reprogramming |
Manfred Boehm (NIH/NHLBI) |
3:30 p.m. - 4:00 p.m. |
Modulating STAT Levels for Regulating Cytokine Effects During Viral Infections: Lessons from NK cells |
Christine Biron (Brown University) |
4:00 p.m. - 4:30 p.m. |
STAT3 & Job's Syndrome |
Steve Holland (NIH/NIAID) |